Literature DB >> 31927152

How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis.

Lucia Taramasso1, Laura Magnasco2, Bianca Bruzzone3, Patrizia Caligiuri4, Giorgio Bozzi5, Sara Mora6, Elisa Balletto2, Paola Tatarelli2, Mauro Giacomini6, Antonio Di Biagio7.   

Abstract

BACKGROUND: It is still unclear what might be the best management of people living with HIV (PLWHIV) with low level viremia (LLV) despite being on antiretroviral treatment (ART).
OBJECTIVES: Aim of our study is to describe the clinical management of PLWHIV with LLV followed in a large cohort. STUDY
DESIGN: Retrospective cohort study.
RESULTS: We included 1607 adult patients over a three-year period (2015-2017). Follow up continued until June, 30th 2019 or last available visit. We observed a low incidence of LLV (0.9 % in 2015, 0.7 % in 2016 and 0.4 % in 2017), with a total of 21 patients with persistent LLV (pLLV), i.e. two consecutive HIV-RNA determinations of 50-500 copies/ml after at least 4 months of viral suppression. Among them, 12 had low compliance to treatment. Genotype resistance test (GRT) was performed in 14 patients and demonstrated at least one resistance mutation in 85.7 %. We described three categories of patients with pLLV: i) those whose ART regimen was not adequate based on GRT; ii) those with presumed suboptimal drug exposure, consequence of low adherence and/or drug-drug interactions and iii) those in which pLLV remained unexplained. For the first two categories, optimization or intensification of ART regimen led to viral suppression in >80 % of patients. We observed only 2 (9.5 %) virological failures and 1 (4.8 %) persistence of LLV in patients who did not switch ART.
CONCLUSIONS: In our cohort, the rate of LLV showed a decline in most recent years. Adherence and previous GRT should be carefully considered with the aim of further reducing the phenomenon.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug resistance mutations; GRT; HIV reservoir; Low level viremia; Residual viremia; Virological failure

Mesh:

Substances:

Year:  2019        PMID: 31927152     DOI: 10.1016/j.jcv.2019.104255

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Genital Shedding of Human Immunodeficiency Virus Type-1 (HIV) When Antiretroviral Therapy Suppresses HIV Replication in the Plasma.

Authors:  Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

Review 2.  HIV: how to manage low-level viraemia in people living with HIV.

Authors:  Emily K Hanners; Jessica Benitez-Burke; Melissa E Badowski
Journal:  Drugs Context       Date:  2022-03-01

3.  HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China.

Authors:  Defu Yuan; Ying Zhou; Lingen Shi; Yangyang Liu; Jing Lu; Jianshuang Chen; Gengfeng Fu; Bei Wang
Journal:  Front Public Health       Date:  2022-07-14

4.  Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.

Authors:  Alain Amstutz; Bienvenu Lengo Nsakala; Fiona Vanobberghen; Josephine Muhairwe; Tracy Renée Glass; Tilo Namane; Tlali Mpholo; Manuel Battegay; Thomas Klimkait; Niklaus Daniel Labhardt
Journal:  PLoS Med       Date:  2020-09-16       Impact factor: 11.069

Review 5.  Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status.

Authors:  Celia Crespo-Bermejo; Eva Ramírez de Arellano; Violeta Lara-Aguilar; Daniel Valle-Millares; Mª Luisa Gómez-Lus; Ricardo Madrid; Luz Martín-Carbonero; Verónica Briz
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.